2014 NET 1-YEAR RANK/COMPANY SALES $M GROWTH

CGT | DECEMBER 2015 | CONSUMERGOODS.COM

1. Johnson & Johnson $14,496 1.0% Consumer

2. Bayer Consumer Health $8,867* 7.7%

3. Glaxosmithkline Consumer $6,574* (9.69%) Healthcare

4. Mead Johnson $4,409 4.97% Nutrition Comp0any

5. Novartis Consumer Health $4,279 5%

OTC Pharmaceut ical Companies

The consumer healthcare market was a hotbed

for mega-deals in 2014, beginning with the

creation of a consumer healthcare joint ven-

ture between Glaxosmithkline and Novartis.

With 2013 pro forma revenues of £6.5 billion, the joint

venture established the No. 1 Wellness OTC franchise

with £3.4 billion sales from major brands, like Excedrin

and Nicorette. One month later, Bayer initiated another

industry shake-up when it agreed to acquire the con-

sumer care business of Merck & Co. Inc., including the

global trademark and prescription rights for Claritin

and Afrin, for $14.2 billion. Sales of the combined OTC

businesses of Merck and Bayer in 2013 amounted to

$7.4 billion. This begs the question: Will J&J’s reign as

market leader come to an end in 2015? Moving up in

the ranks with $3,446 million is Pfizer, Inc.’s Consumer

Healthcare business, which has been steadily building

OTC market presence since re-entering the market

with the $68-billion acquisition of Wyeth in 2009. It had

previously sold its OTC business to J&J in 2006. In 2012,

Pfizer acquired exclusive global rights to market non-

prescription Nexium from AstraZeneca and bought the

company that makes Emergen-C.

TOP

CLICK HERE to go back to the main page and view other verticals: •Top100CGCompanies•PackagedGoods•Food•Beverage•Apparel•OTCPharma•Health&BeautyAids